Immune Checkpoint Inhibitors, Immune-related Adverse Event, Immunotherapy, Predictive Biomarkers
Conditions
Keywords
immunotherapy, immune checkpoint inhibitors, Immune-related Adverse Event, predictive biomarkers, plasmatic cytokines, circulating immune subpopulations
Brief summary
In the last decades, cancer treatment was based on surgery, radiotherapy and chemotherapy. Recently, treatments have largely evolved, first with targeted therapies (notably tyrosin kinase inhibitors, TKI) and then with immune checkpoint inhibitors (ICPI, notably anti-CTLA-4 and anti- PD1). The last ones can induce durable anti-tumoral responses in patients, even if metastases are present. Their mechanisms of action are focused on the activation of immune system in order to eliminate the tumor. ICPI, because of their mechanisms of action, target immune tolerance key components and can induce important immune toxicities (colitis, hepatitis, dermatitis, thyroiditis ...), leading to early discontinuation of treatment, severe or chronic morbidity, and can sometimes be lethal. It is of importance to detect patient at risk of irAEs, because of the increasing use of ICPI and the long- term response capacity in treated patients.
Interventions
BIOLOGICALblood retriewal
blood retriewal for cytokine concentration measurement
Sponsors
Central Hospital Saint Quentin
Centre Hospitalier Universitaire, Amiens
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patient with cancer, whatever initial tumoral histology and disease stage under ICPI treatment (anti-PD1 and/or anti-CTLA-4) * age \> 18 * followed in oncology, pneumology, dermatology, gastroenterology departments of Amiens-Picardie University Hospital or Saint Quentin hospital * who received verbal and written information, and signed the consent form for the study
Exclusion criteria
* non ICPI treated patients * patient who received a first line of ICPI treatment * patient who received or is receiving MEK inhibitors as a treatment (because of possible lower response to ICPI treatment when associated)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Variation from baseline of sIL2R concentration in riAEs patients | 6 months | Variation from baseline of sIL2R concentration (U/mL) in riAEs patients |
| Variation from baseline of IL6 concentration in riAEs patients | 6 months | Variation from baseline of IL6 concentration (pG/mL) in riAEs patients |
| Variation from baseline of IL10 concentration in riAEs patients | 6 months | Variation from baseline of IL10 concentration (pG/mL) in riAEs patients |
| Variation from baseline of IL15 concentration in riAEs patients | 6 months | Variation from baseline of IL15 concentration (pG/mL) in riAEs patients |
| Variation from baseline of IL8 concentration in riAEs patients | 6 months | Variation from baseline of IL8 concentration (pG/mL) in riAEs patients |
| Variation from baseline of INFgamma concentration in riAEs patients | 6 months | Variation from baseline of INFgamma concentration (pG/mL) in riAEs patients |
| Variation from baseline of MCP-1 concentration in riAEs patients | 6 months | Variation from baseline of MCP-1 concentration (pG/mL) in riAEs patients |
| Variation from baseline of MIP 1 alpha concentration in riAEs patients | 6 months | Variation from baseline of MIP 1 alpha concentration (pG/mL) in riAEs patients |
| Variation from baseline of MIP 1 beta concentration in riAEs patients | 6 months | Variation from baseline of MIP 1 beta concentration (pG/mL) in riAEs patients |
| Variation from baseline of sIL6R concentration in riAEs patients | 6 months | Variation from baseline of sIL6R concentration (µG/mL) in riAEs patients |
Countries
France
Contacts
Primary ContactGwladys BOURDENET, DR
Outcome results
None listed